Scarica l'app Stockscreener
9.66
2.72%
-0.27
Dopo l'orario di chiusura:
9.72
0.06
+0.62%
Precedente Chiudi:
$9.93
Aprire:
$10.06
Volume 24 ore:
650.94K
Relative Volume:
0.50
Capitalizzazione di mercato:
$823.27M
Reddito:
-
Utile/perdita netta:
$-119.87M
Rapporto P/E:
-5.337
EPS:
-1.81
Flusso di cassa netto:
$-109.90M
1 W Prestazione:
+4.55%
1M Prestazione:
-12.02%
6M Prestazione:
+15.55%
1 anno Prestazione:
-10.80%
Intervallo 1D:
$9.535
$10.06
Intervallo di 1 settimana:
$8.97
$10.31
Portata 52W:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Confronta ORIC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
9.66 | 964.43M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
Oric Pharmaceuticals (NASDAQ:ORIC) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Signal strength of ORIC Pharmaceuticals Inc. stock in tech scannersWeekly Trend Summary & Free Technical Confirmation Trade Alerts - Newser
Visual trend scoring systems applied to ORIC Pharmaceuticals Inc.Trade Exit Report & Growth Focused Entry Reports - Newser
Wedbush Predicts Weaker Earnings for Oric Pharmaceuticals - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded to Hold at Zacks Research - MarketBeat
Will ORIC Pharmaceuticals Inc. see short term momentumDividend Hike & Safe Capital Growth Tips - Newser
Oric Pharmaceuticals Faces Potential Setbacks Amid Competitors’ Clinical Trials - MSN
Chart Analysts Warn of Resistance Near ORIC Pharmaceuticals Inc. PriceJuly 2025 Levels & Community Verified Trade Signals - newsyoung.net
JPMorgan Chase & Co. Has Lowered Expectations for Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $19.00 Price Target at HC Wainwright - MarketBeat
Market reaction to ORIC Pharmaceuticals Inc.’s recent newsJuly 2025 Intraday Action & Daily Stock Trend Reports - Newser
ORIC Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 Decliners & Accurate Technical Buy Alerts - Newser
Will ORIC Pharmaceuticals Inc. continue its uptrend2025 Price Momentum & Community Driven Trade Alerts - Newser
How to manage a losing position in ORIC Pharmaceuticals Inc.July 2025 Drop Watch & Long Hold Capital Preservation Tips - Newser
Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace
Oric Pharmaceuticals' (ORIC) Buy Rating Reiterated at Guggenheim - MarketBeat
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $12 to $23 - 富途牛牛
How to forecast ORIC Pharmaceuticals Inc. trends using time series2025 Trade Ideas & AI Powered Market Entry Strategies - Newser
Jefferies Reiterates Buy Rating on Oric Pharmaceuticals with $23 Price Target. - AInvest
Guggenheim Reaffirms Buy Rating for ORIC Pharmaceuticals with $18 Target Price. - AInvest
Contineum Therapeutics shares fall 1.04% intraday after ORIC Pharmaceuticals reports positive clinical data and financing activity. - AInvest
Moving Average Trends for ORIC Pharmaceuticals Inc. Stock: What They IndicateWeekly Risk Report & Free Risk Controlled Daily Trade Plans - Newser
Guggenheim Reiterates Buy Rating for ORIC Pharmaceuticals | ORIC Stock News - GuruFocus
Guggenheim Keeps Buy Rating, Raises PT for ORIC Pharmaceuticals to $18. - AInvest
ORIC Pharmaceuticals stock price target raised to $23 by Jefferies - Investing.com Canada
Oric Pharmaceuticals Focuses on Lead Clinical Programs - MSN
ORIC Pharmaceuticals Inc. stock momentum explainedEarnings Miss & High Return Trade Opportunity Guides - Newser
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Can volume confirm reversal in ORIC Pharmaceuticals Inc.Portfolio Return Summary & Precise Buy Zone Tips - Newser
Using flow based indicators on ORIC Pharmaceuticals Inc.Real-Time Investment Signal Forecast with AI - Newser
Using economic indicators to assess ORIC Pharmaceuticals Inc. potentialStrategy Playbook for Risk Controlled Trades - Newser
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharmaceuticals Trims Costs To Back Key Drug Trials - Finimize
Vivo Capital LLC Buys 802,632 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ORIC Pharmaceuticals reports Q2 net loss of $36.4 mln - MarketScreener
What makes ORIC Pharmaceuticals Inc. stock price move sharplySummary of Trade Cycles in 5-Year Range - Newser
Will a bounce in ORIC Pharmaceuticals Inc. offer an exitAI Trend Detection for Entry Timing - Newser
What data driven models say about ORIC Pharmaceuticals Inc.’s futureROI Prediction from Long-Term Holding Plans - Newser
What Fibonacci levels say about ORIC Pharmaceuticals Inc. reboundPrice Forecast Based on AI Analysis - Newser
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):